Nita A. Limdi, Pharm.D., Ph.D., MSPH, FAHANita A. Limdi, Pharm.D., Ph.D., MSPH, FAHA, Ray L. Watts Heersink Endowed Chair and professor in the UAB Department of Neurology, has been inducted as a 2026 Fellow of the Association for Clinical and Translational Science (ACTS). Limdi was recognized during Translational Science 2026, the organization’s annual meeting, as part of the inaugural cohort of the Fellows of ACTS (FACTS) program.
The FACTS program was established in 2026 to honor individuals who have made sustained and significant contributions to clinical and translational science through research, leadership, and service. Limdi was among 36 scientists selected from nearly 6,000 ACTS members nationwide through a competitive nomination and review process.
Limdi’s induction as a Fellow of the ACTS recognizes her sustained contributions to translational science, as well as her commitment to mentorship, team science, and the translation of genomic discoveries into improved patient and population health.
“It is an honor to be selected as a Fellow of the FACTS program,” Limdi said. “I am deeply appreciative that this recognition reflects over two decades of work focused on translating genomic medicine discoveries into clinical care through rigorous implementation. This honor is shared with the many collaborators, colleagues, and trainees who have contributed to and enriched this journey. I am grateful for their partnership and support. It is a privilege to be included among the 2026 Fellows, and I look forward to continuing to advance translational science and improve patient and population health.”
Limdi is a nationally recognized leader in pharmacogenomics, genomic medicine, and pharmacoepidemiology, with more than two decades of experience advancing precision medicine research and clinical implementation. She serves as associate dean for genomic medicine at the UAB Heersink School of Medicine, associate director of the UAB Precision Medicine Institute, program director for pharmacogenomics, and and holds a faculty appointment in the Department of Neurology, where her work aligns closely with cardiovascular and neurovascular health, medication safety, and health equity.
Her research focuses on identifying genetic, clinical, and environmental factors that influence drug response, particularly in anticoagulation therapy and cardiovascular disease. Her work has contributed to improved understanding of treatment variability, including disparities in drug response across populations, and to the development and implementation of genotype-guided therapies in clinical care. Limdi has authored more than 160 peer reviewed publications and has received continuous funding from the National Institutes of Health (NIH).
In her administrative leadership role, Limdi leads efforts to expand UAB’s genomic medicine enterprise through interdisciplinary collaboration, extramural funding, and participation in national research networks. She provides oversight for major initiatives such as the Alabama Genomic Health Initiative, as well as NIH-funded genomic medicine training programs. She is also actively involved in multi-institutional consortia, including the Clinical Pharmacogenetics Implementation Consortium, IGNITE, and the Electronic Medical Records and Genomics (eMERGE) Network.